Nitric oxide-donating aspirin (NO-ASA) is a promising agent for the control of cancer, whose
mechanism of action remains unclear. NF-κB is an important signaling molecule in the …

Estrogen receptor negative (ER (−)) breast cancer is aggressive, responds poorly to current
treatments and has a poor prognosis. The NF-κB signaling pathway is implicated in ER (−) …

Nitric-oxide-donating aspirin (NO-ASA), consisting of ASA (aspirin) plus an-ONO2 moiety
linked to it via a molecular spacer, is a new drug for cancer prevention. NO-ASA seems to …

Nitric oxide-donating aspirin (NO-ASA) is a promising agent for cancer prevention. Although
studied extensively, its molecular targets and mechanism of action are still unclear. S …

Nitric oxide-donating aspirin (NO-aspirin), representing a new concept in the development of
more efficacious nonsteroidal anti-inflammatory drugs, consists of traditional aspirin bearing …

The use of aspirin and other nonsteroidal anti‐inflammatory drugs (NSAIDs) is associated
with a lower risk of colorectal cancer. however, the underlying mechanism is complex and …

Nitric oxide (NO)-releasing aspirin (ASA), consisting of a traditional ASA molecule to which a
NO-donating moiety is covalently bound, is a promising colon cancer chemopreventive …

Substantial evidence indicates that aspirin has antitumour activity against large bowel
cancer and modulation of the NF-kappaB (NF-κB) signalling pathway has been identified as …

Rel/nuclear factor-kappa B (NF-κB) transcription factors are involved in transcription of
several target genes that modulate proliferation, apoptosis and cell growth. TNFα-and IL-1 …

Nitric oxide-releasing aspirin (NO-ASA) is emerging as a potentially important
chemopreventive agent against colon cancer. We examined in HT-29 human colon …